RxDoctor Payments Data

Gustavo Day, MD

Internal Medicine · Dallas, TXNPI 1538239173

Payments from drug & device makers

$62,305in general payments, 2019–2025

Across 1,882 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$30K
  • AstraZeneca$3K
  • GSK$2K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$1,0153%
  • Speaking & faculty fees$5002%
  • Food & beverage$30,21794%
  • Education$2751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring18$30,299
AstraZeneca146$3,303
GSK158$2,249
AbbVie(2 entities)177$2,148
Novo Nordisk141$2,066
Amgen(2 entities)122$1,847
Pfizer93$1,566
Lilly USA, LLC93$1,152
Genentech, Inc.1$1,015
Johnson & Johnson50$990
Boehringer Ingelheim64$986
Abbott35$949
Merck54$917
Amarin Pharma, Inc.42$823
Otsuka America Pharmaceutical, Inc.43$796
Scilex Pharmaceuticals Inc.26$756
E.r. Squibb & Sons, L.L.C.41$732
Novartis45$702
Sunovion Pharmaceuticals Inc.54$667
Astellas Pharma US Inc28$632
Mylan Specialty L.p.44$583
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$532
Supernus Pharmaceuticals, Inc.3$530
Kowa Pharmaceuticals America, Inc.46$413
Sanofi-aventis U.S. LLC29$412
Esperion Therapeutics, Inc.30$392
Bayer17$344
Eisai Inc.31$315
Sumitomo Pharma America, Inc.24$292
Almatica Pharma LLC15$283
Dexcom, Inc.10$280
Ironwood Pharmaceuticals, Inc16$257
Insulet Corporation7$204
Genentech USA, Inc.14$175
Teleflex LLC2$156
Biohaven Pharmaceuticals, Inc.12$150
Nestle Healthcare Nutrition Inc.10$139
Medtronic1$136
MDD US Operations, LLC2$120
Vertex5$104
Shield Therapeutics Inc2$101
Amneal Pharmaceuticals LLC5$99
Axsome Therapeutics, Inc.4$91
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$76
Corcept Therapeutics3$73
Biohaven Pharmaceutical Holding Company Ltd.4$73
Ardelyx, Inc.3$72
Corium, LLC3$68
Vanda Pharmaceuticals Inc.2$63
Viatris Specialty LLC3$60
Arbor Pharmaceuticals, Inc.4$59
Idorsia Pharmaceuticals US Inc4$56
Redhill Biopharma Inc.3$54
Merz North America, Inc.1$54
Nabriva Therapeutics, PLC3$53
Inari Medical, Inc.2$53
Jazz Pharmaceuticals Inc.3$49
Takeda Pharmaceuticals U.S.A., Inc.2$49
Clarus Therapeutics Inc.3$48
Harmony Biosciences LLC2$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,305 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$341,428
Medicare patients
356
Services billed
7,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide604$648,408
MounjaroTirzepatide322$400,815
FarxigaDapagliflozin Propanediol252$254,126
JardianceEmpagliflozin164$209,239
EliquisApixaban119$140,558
EnbrelEtanercept16$122,540
RybelsusSemaglutide42$103,817
IngrezzaValbenazine Tosylate11$94,125
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$86,806
TrulicityDulaglutide62$81,838
LinzessLinaclotide84$79,236
JanuviaSitagliptin Phosphate72$78,854
Repatha SyringeEvolocumab76$74,430
XareltoRivaroxaban73$69,170
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,944$56,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,066$752,225646 claims
Lilly USA, LLCMounjaro, Trulicity$1,152$482,653384 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,303$276,405285 claims
Boehringer IngelheimJardiance, Tradjenta$986$226,300184 claims
PfizerEliquis, Nurtec Odt$1,566$192,836146 claims
AmgenEnbrel, Prolia$1,847$168,07942 claims
AbbVieLinzess, Vraylar$2,148$105,50999 claims
Johnson & JohnsonXarelto, Prezcobix$990$105,49788 claims
GSKTrelegy Ellipta, Breo Ellipta$2,249$103,343120 claims
MerckJanuvia, Janumet$917$99,86784 claims
NovartisEntresto$702$32,28336 claims
Otsuka America Pharmaceutical, Inc.Rexulti$796$30,98314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →